Advertisement

Evolution and Pathogenesis of the Involvement of the Cardiovascular System in HIV Infection

  • G. Barbaro

Abstract

Cardiac illness related to human immunodeficiency virus (HIV) infection tends to occur late in the disease course and is therefore becoming more prevalent as therapy of the viral infection and longevity improve. Autopsy series and retrospective analyses performed before the introduction of highly active antiretroviral therapy (HAART) regimens suggest that cardiac lesions are present in 25–75% of patients with acquired immunodeficiency syndrome (AIDS) [1]. HAART regimens have significantly modified the course of HIV disease, with longer survival rates and improvement of life quality in HIV-infected subjects expected. However, early data raised concerns about HAART being associated with an increase in both peripheral and coronary arterial diseases. HAART is only available to a minority of HIV-infected individuals worldwide, and studies prior to HAART therapy remain globally applicable. As 36.1 million adults and children are estimated to be living with HIV/AIDS and 5.3 million adults and children are estimated to have been newly infected with HIV during the year 2000 [2], HIV-associated symptomatic heart failure may become one of the leading causes of heart failure worldwide. A variety of potential etiologies have been postulated for HIVrelated heart disease, including myocardial infection with HIV itself, opportunistic infections, viral infections, autoimmune response to viral infection, drug-related cardiotoxicity, nutritional deficiencies, and prolonged immunosuppression (Table 1).

Keywords

Infective Endocarditis Pericardial Effusion Simian Immunodeficiency Virus Idiopathic Dilate Cardiomyopathy Myocardial Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators (1998) Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. AIDS Res Hum Retroviruses 14:1071–1077CrossRefPubMedGoogle Scholar
  2. 2.
    Temesgen Z (1999) Overview of HIV infection. Ann Allergy Asthma Immunol 83:1–5PubMedCrossRefGoogle Scholar
  3. 3.
    Barbaro G (2002) Cardiovascular manifestations of HIV infection. Circulation 106:1420–1425CrossRefPubMedGoogle Scholar
  4. 4.
    Barbarini G, Barbaro G (2003) Incidence of the involvement of the cardiovascular system in HIV infection. AIDS 17:S46–S50Google Scholar
  5. 5.
    Holmberg SD, Moorman AC, Williamson JM et al (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748CrossRefPubMedGoogle Scholar
  6. 6.
    Bozzette SA, Ake CF, Tam HK et al (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702–710CrossRefPubMedGoogle Scholar
  7. 7.
    Friis-Moller N, Weber R, Reiss P et al (2003) Cardiovascular risk factors in HIV patients: association with antiretroviral therapy: results from DAD study. AIDS 17:1179–1193CrossRefPubMedGoogle Scholar
  8. 8.
    Klein D, Hurley LB, Quesenberry Jr CP, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J AIDS 30:471–477Google Scholar
  9. 9.
    Coplan PM, Nikas A, Japour A et al (2003) Incidence of myocardial infarction in randomized trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 19:449–455CrossRefPubMedGoogle Scholar
  10. 10.
    Mary-Krause M, Cotte L, Simon A et al and the Clinical Epidemiology Group from the French Hospital Database (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17:2479–2486CrossRefPubMedGoogle Scholar
  11. 11.
    Barbaro G, Di Lorenzo G, Cirelli A et al (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 25:2405–2418CrossRefPubMedGoogle Scholar
  12. 12.
    The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003CrossRefGoogle Scholar
  13. 13.
    The Data Collection on Adverse Events of AntiHIV Drugs (DAD) Study Group (2007). Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723–1735CrossRefGoogle Scholar
  14. 14.
    Stein KM, Haronian H, Mensah GA et al (1990) Ventricular tachycardia and Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 66:888–889CrossRefPubMedGoogle Scholar
  15. 15.
    Aoun S, Ramos E (2000) Hypertension in the HIV-infected patient. Curr Hypertens Rep 2:478–481CrossRefPubMedGoogle Scholar
  16. 16.
    Sattler FR, Qian D, Louie S et al (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15:2001–2010CrossRefPubMedGoogle Scholar
  17. 17.
    Gazzaruso C, Bruno R, Garzaniti A et al (2003). Hypertension among HIV patients: prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 21:1377–1382CrossRefPubMedGoogle Scholar
  18. 18.
    Crane H, Van Rompaey S, Kitahata M (2006) Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20:1019–1026CrossRefPubMedGoogle Scholar
  19. 19.
    Heidenreich PA, Eisenberg MJ, Kee LL et al (1995) Pericardial effusion in AIDS: incidence and survival. Circulation 92:3229–3234PubMedGoogle Scholar
  20. 20.
    Barbaro G, Fisher SD, Lipshultz SE (2001) Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 1:115–124CrossRefPubMedGoogle Scholar
  21. 21.
    Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators (1998) Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. AIDS Res Hum Retroviruses 14:1071–1077CrossRefPubMedGoogle Scholar
  22. 22.
    Lai WW, Lipshultz SE, Easley KA et al (1998) Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus-infected women: the prospective P2C2 HIV Multicenter Study. P2C2 HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland. J Am Coll Cardiol 32:1749–1755Google Scholar
  23. 23.
    Barbaro G, Di Lorenzo G, Soldini M et al (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 100:933–939PubMedGoogle Scholar
  24. 24.
    Pugliese A, Isnardi D, Saini A et al (2000) Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 40:282–284CrossRefPubMedGoogle Scholar
  25. 25.
    Bijl M, Dieleman JP, Simoons M, Van Der Ende ME (2001) Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J AIDS 27:318–320Google Scholar
  26. 26.
    Nzuobontane D, Blackett KN, Kuaban C (2002) Cardiac involvement in HIV-infected people in Yaounde, Cameroon. Postgrad Med J 78:678–681CrossRefPubMedGoogle Scholar
  27. 27.
    Shannon RP, Simon MA, Mathier MA et al (2000) Dilated cardiomyopathy associated with simian AIDS in nonhuman primates. Circulation 101:185–193PubMedGoogle Scholar
  28. 28.
    Barbaro G (2003) Pathogenesis of HIV-associated heart disease. AIDS 17:S12–S20CrossRefPubMedGoogle Scholar
  29. 29.
    Currie PF, Goldman JH, Caforio AL et al (1998) Cardiac autoimmunity in HIV-related heart muscle disease. Heart 79:599–604PubMedGoogle Scholar
  30. 30.
    Lipshultz SE, Easley KA, Orav EJ et al (2000) Cardiac dysfunction and mortality in HIV-infected children: the Prospective P2C2 HIV Multicenter study. Circulation 102:1542–1548PubMedGoogle Scholar
  31. 31.
    Freeman GL, Colston JT, Zabalgoitia M, Chandrasekar B (1998) Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol 274:249–258Google Scholar
  32. 32.
    Lipshultz SE, Easley KA, Orav EJ et al (1998) Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV multicenter study. Circulation 97:1246–1256PubMedGoogle Scholar
  33. 33.
    Cooper ER, Hanson C, Diaz C et al (1998) Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. J Pediatr 132:808–812CrossRefPubMedGoogle Scholar
  34. 34.
    Miller TL, Orav EJ, Colan SD, Lipshultz SE (1997) Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 66:660–664PubMedGoogle Scholar
  35. 35.
    Miller TL (1998) Cardiac complications of nutritional disorders. In: Lipshultz SE (ed) Cardiology in AIDS. Chapman and Hall, New York, pp 307–316Google Scholar
  36. 36.
    Hoffman M, Lipshultz SE, Miller TL (1999) Malnutrition and cardiac abnormalities in the HIV-infected patients. In: Miller TL, Gorbach S (eds) Nutritional aspects of HIV infection. Arnold, London, pp 33–39Google Scholar
  37. 37.
    Lewis W, Simpson JF, Meyer RR (1994) Cardiac mitochondrial DNA polymerase gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 74:344–348PubMedGoogle Scholar
  38. 38.
    Lewis W, Grupp IL, Grupp G et al (2000) Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 80:187–197CrossRefPubMedGoogle Scholar
  39. 39.
    Lipshultz SE, Easley KA, Orav EJ et al (2000) Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 343:759–766CrossRefPubMedGoogle Scholar
  40. 40.
    Barbaro G, Klatt EC (2002) HIV infection and the cardiovascular system. AIDS Rev 4:93–103PubMedGoogle Scholar
  41. 41.
    Nahass RG, Weinstein MP, Bartels J, Gocke DJ (1990) Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and-positive patients. J Infect Dis 162:967–970PubMedGoogle Scholar
  42. 42.
    Johnson RM, Little JR, Storch GA (2001) Kawasaki-like syndromes associated with human immonodeficiency virus infection. Clin Infect Dis 32:1628–1634CrossRefPubMedGoogle Scholar
  43. 43.
    Shingadia D, Das L, Klein-Gitelman M, Chadwick E (1999) Takayasu’s arteritis in a human immunodeficiency virus-infected adolescent. Clin Infect Dis 29:458–459CrossRefPubMedGoogle Scholar
  44. 44.
    Gisselbrecht M (1999) Vasculitis during human acquired immunodeficiency virus infection. Pathol Biol (Paris) 47:245–247Google Scholar
  45. 45.
    Chi D, Henry J, Kelley J et al (2000) The effects of HIV infection on endothelial function. Endothelium 7:223–242PubMedGoogle Scholar
  46. 46.
    Berger O, Gan X, Gujuluva C et al (1999) CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 5:795–805PubMedGoogle Scholar
  47. 47.
    Twu C, Liu QN, Popik W et al (2002) Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 99:14386–14391CrossRefPubMedGoogle Scholar
  48. 48.
    Grahame-Clarke C, Alber DG, Lucas SB et al (2001) Association between Kaposi’s sarcoma and atherosclerosis: implications for gammaherpesviruses and vascular disease. AIDS 15:1902–1905CrossRefPubMedGoogle Scholar
  49. 49.
    Barbaro G, Barbarini G, Pellicelli AM (2001) HIV-associated coronary arteritis in a patient with f atal myocardial infarction. N Engl J Med 344:1799–1800CrossRefPubMedGoogle Scholar
  50. 50.
    Arsura EL, Ismail Y, Freeman S, Karunakav AR (1994) Amphotericin B-induced dilated cardiomyopathy. Am J Med 97:560–562CrossRefPubMedGoogle Scholar
  51. 51.
    Cohen AJ, Weiser B, Afzal Q, Fuhrer J (1990) Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG). AIDS 4:807–809CrossRefPubMedGoogle Scholar
  52. 52.
    Lopez JA, Harold JG, Rosenthal MC et al (1987) QT prolongation and Torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59:376–377CrossRefPubMedGoogle Scholar
  53. 53.
    Dal Maso L, Serraino D, Franceschi S (2001) Epidemiology of HIV-associated malignancies. Cancer Treat Res 104:1–18Google Scholar
  54. 54.
    Barbaro G, Klatt EC (2003) Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 9:1475–1481CrossRefPubMedGoogle Scholar
  55. 55.
    Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51–F58CrossRefPubMedGoogle Scholar
  56. 56.
    Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17:S141–S148CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • G. Barbaro
    • 1
  1. 1.Department of Medical Pathophysiology“Sapienza” University of RomeRomeItaly

Personalised recommendations